Navigation Links
Antibacterial Drugs Market Expected to Reach USD 38.9 Billion Globally in 2023, at CAGR of 1.3% From 2015 to 2023: Transparency Market Research
Date:7/15/2015

ALBANY, New York, July 15, 2015 /PRNewswire/ --

According to a new market report published by Transparency Market Research "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023," the global antibacterial drugs market was valued at USD 43.9 billion in 2014 and is estimated to reach USD 38.9 billion by 2023 at a CAGR of 1.3% from 2015 to 2023.

Antibacterial drugs have been utilized by humans since the discovery of the first antibiotic penicillin in 1928 by Alexander Fleming and has evolved into a multi-billion dollar market. These drugs treat infectious diseases caused by gram positive, gram negative, aerobic and anaerobic bacteria that cannot be treated by any other method unlike other diseases, where substitute methodologies are available. This property has made antibacterial drugs an indispensable part of human health care. Over the period, the bacteria have genetically mutated giving rise to multi-drug resistant (MDR) variants. The prevalence of MDR bacterial infections is also on a hike; according to World Health Organization (WHO) in 2013, there were about 480 000 new cases of multidrug-resistant tuberculosis (MDR-TB); extensively drug-resistant tuberculosis (XDR-TB) has been identified in 100 countries. MDR-TB requires treatment courses that are much longer and less effective than those for non-resistant TB.

To browse through the ToC or purchase the Antibacterial Drugs Market Report, please visit: http://www.transparencymarketresearch.com/antibacterial-drugs-market.html

Antibacterial drugs are classified into eight major classes, namely, aminoglycosides, B-Lactams, tetracyclines, sulfonamides, quinolones, macrolides, phenicols and miscellaneous antibacterials. The B-lactams class was the largest segment of the global antibacterial drugs market in 2014, with 58% share. Quinolones was identified as the second largest class, which held a share of 17% of the global antibacterial drugs market in 2014 and is expected to report a negative CAGR during the forecast period. This decline in revenue will be primarily witnessed due to sales erosion from patent expiries, evolution of resistant strains of bacteria and rising concerns regarding tendon ruptures and tendon damage from fluoroquinolones administration. However, the demand for macrolides and quinolones/fluoroquinolones classes will remain high during the forecast period, due to their usage in treating a large number of infections coupled with expected launch of pipeline drugs in these classes during the forecast period.

Get report sample PDF copy from here: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1567

The key drugs in pipeline have been identified for this market (currently in phase III clinical trials) and sales forecast has been provided for those expected to be launched during the forecast period (2015 to 2022). These include solithromycin (Cempra, Inc.), VivaGel (SPL7013) (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. These drugs promise to provide improved efficacy, shorter onset of action and fewer side effects as compared to the currently available antibacterial drugs. Hence, future commercialization of these drugs during the forecast period is anticipated to have a profound impact on the growth of the overall antibacterial drugs market.

Browse the Press Release of this report, here: http://www.transparencymarketresearch.com/pressrelease/antibacterial-drugs-market.htm

AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players operating in the global antibacterial drugs market. These players have worldwide presence in the pharmaceutical industry and are involved in constant competition with each other. Pfizer, Inc. was observed to be the leading player in the antibacterial drugs market. Major end-users for antibacterial drugs include hospitals, private clinics, physicians and patients.

Browse the Article of this report, here: http://www.transparencymarketresearch.com/article/antibacterial-drugs-market.htm

The global antibacterial drugs market has been segmented as below:

Global Antibacterial Drugs Market, by Drug Class, 2013 - 2023 (USD Million) 

  • Aminoglycosides
  • B-Lactams
  • Tetracyclines
  • Sulfonamides
  • Quinolones/Fluoroquinolones
  • Macrolides
  • Phenicols
  • Miscellaneous Antibacterials

Browse the all Pharmaceuticals Market Research Reports, here: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

Pipeline Analysis of Antibacterial Drugs Market 

  • Actoxumab/Aezlotoxumab, (MK-3415A)
  • Surotomycin (MK-4261)
  • Arikace
  • Cadazolid 
  • Ciprofloxacin/Fluocinolone Acetonide 
  • Zempia (E-101)
  • Carbavance (meropenem/RPX7009)
  • Ozenoxacin
  • RHB-105
  • SPL7013
  • Delafloxacin
  • Solithromycin (CEM-101)
  • Eravacycline
  • Delamanid 
  • SYM-1219
  • Omadacycline (PTK-0796)
  • Plazomycin

Global Antibacterial Drugs Market, by Geography, 2013 - 2023 (USD Million) 

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Rest of the World (RoW)

Other Published Reports by Transparency Market Research: 

About Us 

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. 

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Blog: http://www.europlat.org



'/>"/>
SOURCE Transparency Market Research
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Development and Commercialization of Antibacterial Drugs to Speed Up
2. Antibacterial Drugs Market (By Class and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
3. Generic Drugs Market Forecast 2015-2025: Opportunities For Leading Companies
4. China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal
5. New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State
6. Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies
7. Information Update - Health Canada requests quarantine of drugs linked to Polydrug Laboratories due to data integrity concerns
8. Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025
9. Nearly Half Of Opioid Painkiller Users Unaware They Are Taking Drugs As Addictive As Heroin
10. Boston Healthcare Report Describes How Understanding of the Therapeutic Value of Cancer Drugs Increases after Initial FDA Approval
11. Information Update - Forxiga, Invokana: Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2019)... ... August 21, 2019 , ... ... Healthcare’s Construction and Design Survey, has added Operational Readiness to its integrated ... overlay to clients’ capital projects, working with the clinical and operational leadership ...
(Date:8/21/2019)... ... August 21, 2019 , ... ... Module for its voice-activated notification and communication solution—with new features to help ... discharged patients. , Leveraging the innovative Amazon Alexa voice assistance technology, ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... hosting their 2nd Annual National Sports Summit, August 25-26 at the Hyatt Place ... clinical leaders from all major professional sports programs to discuss progress made over ...
Breaking Medicine Technology:
(Date:8/17/2019)... ... August 17, 2019 , ... ... America’s Fastest-Growing Private Companies—the Inc. 5000 , For the 2nd Year In a ... Revenue Growth of 192% Percent , Inc. magazine today revealed that YellowTelescope LLC ...
(Date:8/16/2019)... ... August 16, 2019 , ... The clinical trial supply chain landscape is constantly ... , Join Just In Time Manufacturing Solutions Manager at Almac Clinical Services , ... 11am EDT (4pm BST/UK) on a journey through time as it relates to clinical ...
(Date:8/16/2019)... ... August 16, 2019 , ... ... market, has joined the esteemed Haute Beauty Network. , The Haute Beauty Network, ... to present Dr. Arnaoutakis as a hair restoration expert and our newest addition ...
(Date:8/15/2019)... ... 15, 2019 , ... With many students either starting college for the first time, and returning ... to the CDC , “there are about 20 million new cases of STDs each ... ages of 15 and 24. Young people are at greater risk of getting an STD.” ...
(Date:8/14/2019)... ... August 14, 2019 , ... Teguar Corporation has claimed the ... This list has long-been established as a mark of success for some of Americas ... Oracle. Teguar made the list in 2015, 2016 and 2017. This year, Teguar secured ...
Breaking Medicine News(10 mins):